ANTH
Anthera Pharmaceuticals, Inc.
Set alert
0.00 USD 0.00 0.00%
0.0001 Day range 0.0001
0.00 52-week range 0.001
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0001
- Prev close
- 0.0001
- Mkt cap
- 2.62K
- Vol
- 23.89K
- Avg vol
- 1.20K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0001
- Forward P/E
- -0.04
- Beta
- 2.27
- Short ratio
- 2.09
- Inst. own
- 4.11%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.072222
- 200-d avg
- 0.139645
- 1y target
- 3.00
Key statistics
- Market cap
- 1.60M
- Enterprise value
- -6.31M
- Trailing P/E
- 0.00
- Forward P/E
- -0.04
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.29
- EPS (TTM)
- -1.76
- Beta
- 2.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -17.92M
- Total cash
- 8.09M
- Total debt
- 0
- Return on equity
- -568.85%
- Shares outstanding
- 26.18M
- Short % of float
- 10.45%
- 50-day average
- 0.072222
- 200-day average
- 0.139645
Analyst view
Consensus: buy
Buy
Price target (mean) 3.00
Ratings (0m) 5 2 buy · 3 hold · 0 sell
- Strong buy0
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ANTH Revenue — quarterly 0
ANTH Net income — quarterly -7.72M
ANTH EPS — quarterly -0.42
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 15, 2018 | Mar 1, 2018 | -0.60 | -0.42 | +0.18 | +30.00% |
| Mar 5, 2018 | Dec 1, 2017 | -0.71 | -0.73 | -0.02 | -2.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 20, 2018 | Roth Capital | init | — | Buy |
| Dec 28, 2016 | Jefferies | down | — | Hold |
| Dec 28, 2016 | Citigroup | down | — | Neutral |
| Sep 16, 2015 | Citigroup | init | — | Buy |
| May 11, 2015 | Citigroup | up | — | Neutral |
| Mar 4, 2013 | Jefferies | init | — | Buy |
About Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anthera.com
News
- AMD and Cerbras Create A New Blueprint For Hardware
- SpaceX Lost $1 Trillion In A Week. So Why Did Bond Investors Rush To Lend It $20 Billion?
- Anthera Pharmaceuticals (OTCMKTS:ANTH) Shares Cross Above Two Hundred Day Moving Average – What’s Next?
- Anthera Pharmaceuticals (OTCMKTS:ANTH) Stock Passes Above Two Hundred Day Moving Average – What’s Next?
- Anthera Pharmaceuticals (OTCMKTS:ANTH) Shares Cross Above Two Hundred Day Moving Average – What’s Next?
- AM Best Assigns Issue Credit Ratings to Anthem, Inc.'s New Senior Unsecured Notes
- AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Announcement
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Highs On Tuesday
- Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on ANTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| OLSON CHARLES V | Chief Technology Officer | Stock Award(Grant) | Jan 10, 2017 | 17,519 |
| THOMPSON JOHN CRAIG | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 6, 2017 | 17,590 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wedbush Securities Inc | 0.81% | 210,914 | 25.31K | Jun 29, 2018 |
| CALPERS (California-Public Employees Retirement System) | 0.05% | 12,765 | 1.53K | Jun 29, 2018 |
| Meeder Asset Management, Inc. | 0.03% | 9,035 | 1.08K | Jun 29, 2018 |
| Ladenburg Thalmann Financial Services Inc. | 0.01% | 1,500 | 179 | Jun 29, 2018 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.06% | 276,716 | 439.98K | Dec 30, 2017 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.10% | 27,078 | 43.05K | Dec 30, 2017 |
| Invesco ETF Tr-Invesco Wilshire Micro Cap ETF | 0.02% | 4,710 | 565 | Jun 29, 2018 |
| Vanguard Balanced Index Fund | 0.01% | 3,900 | 6.20K | Dec 30, 2017 |
| Meeder Funds-Spectrum Fund | 0.01% | 2,983 | 4.74K | Dec 30, 2017 |